Injectable HydrogelâMicrosphere Construct with Sequential

Subscriber access provided by Fudan University

Article

Injectable Hydrogel-Microsphere Construct with Sequential Degradation for Locally Synergistic Chemotherapy Yuhao Zheng, Yilong Cheng, Jinjin Chen, Jianxun Ding, Mingqiang Li, Chen Li, Jin-Cheng Wang, and Xuesi Chen ACS Appl. Mater. Interfaces, Just Accepted Manuscript • DOI: 10.1021/acsami.6b15245 • Publication Date (Web): 09 Jan 2017 Downloaded from http://pubs.acs.org on January 10, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

ACS Applied Materials & Interfaces is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ACS Applied Materials & Interfaces

Injectable Hydrogel−Microsphere Construct with Sequential Degradation for Locally Synergistic Chemotherapy Yuhao Zheng,†,‡ Yilong Cheng,‡ Jinjin Chen,‡ Jianxun Ding,*,‡ Mingqiang Li,‡ Chen Li,† Jincheng Wang,*,† and Xuesi Chen‡ †

Department of Orthopedics, Second Hospital of Jilin University, Changchun 130041, P. R.

China ‡

Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese

Academy of Sciences, Changchun 130022, P. R. China

ACS Paragon Plus Environment

1


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 2 of 27

KEYWORDS: thermo-sensitive hydrogel, microsphere, sequential drug release, osteosarcoma, synergistic chemotherapy

ABSTRACT: In recent years, in situ chemotherapy mediated by biodegradable polymer platforms has attracted increasing attention. Herein, an advanced drug delivery system, combretastatin A-4 (CA4) and docetaxel (DTX)-loaded microsphere embedded in injectable thermo-sensitive polypeptide hydrogel (i.e., hydrogel−microsphere (Gel−MP) construct), was reported for sequential release of drugs with different mechanisms to treat osteosarcoma synergistically. The Gel−MP construct showed sequential biodegradability and excellent biocompatibility. CA4 was preferentially released from hydrogel with faster degradation to disturb tumor vascular and reduce the exchange of nutrients between tumor and surrounding tissues, which created tissue interstitial space for DTX penetration to inhibit tumor cell proliferation. The in vivo treatment with Gel/CA4−MP/DTX efficiently suppressed the growth of mouse K7 osteosarcoma compared to other formulations. More importantly, by systematical study of histopathology and immunohistochemistry, the Gel−MP construct can significantly upregulate anti-proliferation effect and reduce toxicity of drugs. Therefore, this injectable and locally sequential delivery system has a bright prospect in clinical application of in situ synergistic chemotherapy.


2

Page 3 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


1. Introduction Osteosarcoma is a primary malignant bone tumor in childhood and adolescence,1-2 with the incidence rate of about 4.0 or 5.0 for the ranges of 0−14 or 0−19 years per year per million persons, which accounts for eighth in the incidence of childhood malignancies.3 Currently, the combination of preoperative, operative, and postoperative neoadjuvant chemotherapy constitutes the standard treatment program of osteosarcoma.4 After standard treatment, the 5-year survival rate for osteosarcoma without metastasis is about 60% − 70%, which is limited to only 30% for those with metastasis.5 Although chemotherapy is still considered as the first choice to treat osteosarcoma, the disappointing pharmacokinetics and serve systemic toxicity of small molecular drugs (SMDs) are the major concerns for patient compliance, which encourage researchers to exploit efficacious system to address these issues.6-9 Recently, many studies have focused on the in situ drug delivery systems, like polymer thermo-sensitive hydrogels (Gels).10-11 Chemotherapy drugs can be facilely dispersed into the thermo-responsive polymer solution at low temperature, e.g., 4 °C, without the usage of organic solvent, and the drug release depot is automatically formed in situ under the stimuli of body temperature. The local injection is easily manipulated through syringe and could minimize the surgical trauma. Compared with the systemic administration of chemotherapy drugs, the local and continuous drug release from the Gels in the tumor site can effectively improve the efficacies and reduce the systemic toxicity of drugs.12-14 Microspheres (MPs) are widely used in controlled drug delivery to treat various diseases.15 Currently, a lot of polymers have been used to prepare MPs.16-17 Among them, the biodegradable synthetic polymer, poly(lactic-co-glycolic acid) (PLGA), has received widespread attention.18 Previous studies have shown that the PLGA MPs can entrap a variety of SMDs, such as 5-


3


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 4 of 27

fluorouracil (5-FU), cisplatin (CDDP), dexamethasone (DMS), docetaxel (DTX), doxorubicin (DOX), and paclitaxel (PTX).16 The SMDs-loaded MPs can steadily release the encapsulated drugs with the gradual degradation of PLGA backbone to achieve a long-term sustained administration. Nowadays, the combination of vascular disrupting agents and cytotoxic drugs has been reported to have improved antitumor efficacy, which can induce the wholly regional apoptosis of tumors.19 Combretastatin A-4 (CA4) can destroy the structure of blood vessel by binding the tubulin of endothelial cells and finally induce tumor necrosis by blocking the transmission of oxygen and other necessary nutritions.20 CA4 played a significant role on the proliferation stage of the blood vessel endothelial cells in vitro, whereas had little effect in the quiescent stage.21 Since the antitumor effect of CA4 can only act on the internal tumor tissues with rich peripheral vascular proliferation and has no proliferation inhibition effect on tumor cells, it is often the cause of tumor treatment failure and recurrence.22 Fortunately, the cells at the edge of tumor with rich blood vessels are sensitive to the traditional chemotherapy drugs, and it enables us to explore the alternative strategy to sequentially deliver CA4 and cytotoxic drugs. However, the synergistic therapeutic effects are often unsatisfied by intravenous injection, which mainly result from short circulating half-life in vivo and unselective biodistribution.23 Additionally, the sequence of administration is also important in the combination of CA4 and cytotoxic drugs. If the peripheral tumor cells were killed by cytotoxic drugs firstly, the tumor cells within the solid tumors will be survived, which will cause the tumor recurrence and metastasis. For this issue, an injectable construct of MP-loaded thermo-sensitive Gel with stepwise degradation was prepared to sequentially deliver CA4, a vascular disrupting drug, and docetaxel (DTX), a cytotoxic agent, for the treatment of osteosarcoma in this study. As shown in Scheme 1,


4

Page 5 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


CA4 is released preferentially, which destructs neovascularization and inhibits the formation of new blood vessels, followed by reducing exchange of nutrients between tumor and surrounding tissues to kill the tumor cells inside. Then, the sustained release of DTX leads to the destruction of the surface cells of tumor and causes the wholly regional apoptosis of tumor. Our work demonstrates that the construct of hydrogel−microsphere (Gel−MP) has a bright application prospect in the in situ chemotherapy of malignancies.

Scheme 1. Sequential drug delivery with Gel−MP construct. Preparation of Gel/CA4−MP/DTX for two-pronged locally synergistic chemotherapy of osteosarcoma. 2. MATERIALS AND METHODS


5


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 6 of 27

2.1. Materials. All the materials used in this work have been described in Supporting Information. 2.2. Fabrication and Characterizations of Gel−MP Construct. 2.2.1. Preparations and Characterizations of Gel and MP. The copolymer of poly(L-alanineco-L-phenylalanine)-block-poly(ethylene glycol)-co-poly(L-alanine-co-L-phenylalanine) (PLAFb-PEG-b-PLAF) was synthesized through the ring-opening polymerization (ROP) of L-Alanine N-carboxyanhydride (L-Ala NCA) and L-phenylalanine N-carboxyanhydride (L-Phe NCA) using amino-terminated poly(ethylene glycol) (NH2-PEG-NH2) as a macroinitiator, as depicted in supplementary Scheme S1.24 The blank and DTX-loaded MPs were prepared through a water-inoil-in-water (W1/O/W2) double emulsion technique. The detailed procedures for preparations and characterizations of Gel and MP were described in Supporting Information. 2.2.2. Preparation of Drug-Loaded Gel−MP. The concentration of DTX-entrapped PLGA MP (MP/DTX) was decided according to its drug loading content (DLC; 9.88 wt.%) and the required dose of DTX at 15.0 mg per kg body weight (mg (kg BW)−1 for tumor inhibition in vivo. The concentration of CA4 was determined based on the used dose of CA4 at 25.0 mg (kg BW)−1. For the preparation of Gel/CA4−MP/DTX, 8.0 wt.% PLAF-b-PEG-b-PLAF with 3.9 wt.% MP/DTX and 0.5 wt.% CA4 was dissolved together in phosphate-buffered saline (PBS). The mixed system was stirred at 4 °C for three days to obtain a homogeneous solution. Gel/CA4−MP and Gel−MP/DTX were prepared through dispersing different components with the same proposal. 2.2.3. In Vitro Degradation and Release Profiles of Gel/CA4−MP/DTX. 0.5 mL of Gel/CA4−MP/DTX solution was added to the vial with the inner diameter of 11 mm and placed at 37 °C for 30 min. After gelation, Gel/CA4−MP/DTX was weighed, and then 2.0 mL of PBS without or with 2.0 mg mL−1 of elastase, mimicking the degradation microenvironment in vivo,


6

Page 7 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


was slowly injected into the upper layer of Gel. Subsequently, the vial was placed into the oscillation at 37 °C with continuous shaking at 70 rpm. The upper buffers were collected and replaced by fresh buffer, and the remained Gel was weighted every other day. The weight change of Gel/CA4−MP/DTX in the entire process was collected to show the degradation profile. After the completion of Gel/CA4−MP/DTX degradation, the concentrations of two drugs in the reserved degradation solution were measured by high-performance liquid chromatography (HPLC; Waters 1525 system with a Waters C18 column and a Waters 2489 ultraviolet/visible (UV/vis) detector, Waters, Milford, MA, USA). Acetonitrile−water (60:40, V/V) was used as elution with a flow rate of 1.0 mL min−1. The absorption wavelength (λabs) was set at 230 nm, and Breeze software was used for datum analyses. The peak of DTX appeared at 6 min and the peak of CA4 appeared at 6.5 min. 2.2.4. In Vivo Degradation and Biocompatibility of Gel−MP Construct. Sprague-Dawley rats were used for the evaluation of in vivo degradation and biocompatibility of Gel−MP construct. The polypeptide with 5.0 wt.% MP was dissolved in PBS with the concentration of 8 wt.%. The solution was stirred at 4 °C for three days. 500.0 µL of Gel−MP solution was subcutaneously injected into the back of rats. The rats were sacrificed at the predetermined time points (30 min, and 7, 14, 21, 28, 35, and 42 days). The Gel-located skin was collected and fixed in 4.0% (W/V) paraformaldehyde solution. The tissues were embedded into paraffin and cut into sections of 5 μm. Tissue sections were stained with hematoxylin and eosin (H&E) for pathology and organ damage analyses. 2.3. Tumor-Bearing Mouse Model Assessments 2.3.1. Animal Procedures. Eighty 8-week-old BALB/c male mice were purchased from the Experimental Animal Center of Jilin University and divided into eight groups. The animal


7


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 8 of 27

experiments were performed according to the protocol approved by the Institutional Animal Care and Use Committee of Jilin University. The tumor-bearing mice were prepared through the subcutaneous injection in the armpits of right anterior limbs with 0.1 mL of cell suspension containing 2.0 × 106 mouse K7 osteosarcoma cells in PBS. 2.3.2. In Vivo Antitumor Efficacy. The tumor-bearing mice weighing about 20 g were raised in the same condition. When the tumors grew to about 150 mm3, 100.0 μL of different formulations were peritumorally injected. The formulations were abbreviated as follows: Group 1: PBS as control group (Control); Group 2: blank MP-loaded Gel group (Gel−MP); Group 3: group of 5.0 mg mL−1 free CA4 in PBS (CA4); Group 4: group of 3.0 mg mL−1 free DTX in PBS (DTX); Group 5: group of free CA4 and free DTX at a concentration of 5.0 and 3.0 mg mL−1 in PBS, respectively (CA4+DTX); Group 6: CA4 and blank MP-loaded Gel group (Gel/CA4−MP); Group 7: group of Gel with DTX-loaded MP (Gel−MP/DTX); Group 8: CA4 and MP/DTX coloaded Gel (Gel/CA4−MP/DTX). The treatment doses of CA4 and DTX was 25.0 and 15.0 mg (kg BW)−1, respectively. The tumor sizes were measured every two days by vernier calipers. The tumor volume (V; mm3) was calculated using Eq. (3). V (mm3 ) =

L × S2 2

(1)

In Eq. (3), L and S (mm) were the largest and smallest diameters of tumor, respectively. In addition, the body weight and survival rate were monitored in 26 days after all treatments, and all the rest of the mice were sacrificed. The entire tumor and major organs (i.e., the heart, liver, spleen, lung, and kidney) were isolated. 2.4. Histological and Immunohistochemical Analyses. The collected tumors and major organs were fixed in 4% (W/V) PBS-buffered paraformaldehyde overnight, and then embedded in paraffin. The paraffin-embedded tumors were cut into about 5 μm sections for H&E staining


8

Page 9 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


and about 3 μm sections for immunohistochemical analyses. Immunohistochemical staining was carried out following the reported immunocytochemistry protocol previously.25-26 The histological and immunohistochemical alterations were detected by a microscope (Nikon Eclipse Ti, Optical Apparatus Co., Ardmore, PA, USA) and subsequently analyzed with ImageJ software (National Institutes of Health, Bethesda, Maryland, USA).

Figure 1. Morphologies and scales of MP, Gel, and Gel−MP construct. (A) SEM microimage and (B) average size of MP. (C) SEM microimages of Gel and (D) Gel−MP construct. 3. RESULTS AND DISCUSSION 3.1. Preparation and Characterization of Injectable Gel−MP Construct. As shown in supplementary Scheme S1, PLAF-b-PEG-b-PLAF was synthesized through the ROP of L-Ala NCA and L-Phe NCA in the presence of NH2-PEG-NH2, and the chemical structure was


9


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 10 of 27

characterized by proton nuclear magnetic resonance (1H NMR) spectrum (Figure S1, Supporting information). The degrees of polymerization (DPs) of L-Ala and L-Phe unites were analyzed to be 30 and 4 by the integral of peaks at 4.67 and 4.41 ppm to that at 3.67 ppm, respectively. The number-average molecular weight (Mn) and molecular weight distribution (polydispersity index, PDI) were determined to be 6720 g mol and 1.47 by

1

H NMR and gel permeation

chromatography (GPC), respectively. The PLGA MP was prepared through the W1/O/W2 double emulsion technique. The scanning electron microscope (SEM) microimage showed that MP had excellent balling effect and smooth surface (Figure 1A), and the average size of MP was around 2.94 μm (Figure 1B). DTX can be efficiently loaded into MP with 9.88 wt.% of DLC and 98.8 wt.% of drug loading efficiency (DLE). Therefore, the PLGA MP is considered as a promising platform to encapsulate and diver DTX. The PLAF-b-PEG-b-PLAF solution underwent sol−gel−precipitation transition with the increase of temperature, and the transition temperature was dependent on the concentration of polypeptide solution. As shown in Figure 2A, the sol−gel transition temperature decreased with the increase of polypeptide concentration, and the gel−precipitation temperature showed an opposite trend. The polypeptide solution with a concentration of 8 wt.% existed as fluid with low viscosity, and underwent a fast sol−gel transition at around 29 °C, both of which revealed the great potential as an injectable material. The phase diagram of Gel−MP construct is similar as blank gel, and the addition of MP into polypeptide solution decreased the gelation temperature attributed to the enhanced interaction between Gel and MP (Figure 2B). The rheology changes of polypeptide solutions with/without MP were also evaluated (Figure 2C and 2D), and storage moduli (G′s) both increased as temperature went up. Moreover, the gelation temperatures obtained from the cross-point of G′ and loss moduli (G′′s) were consistent with those by vial


10

Page 11 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


inverting method. In addition, the addition of drugs also suppressed the gelation temperature, and upregulated G′ and G′′, as shown in Figure S2, Supporting Information. The results should be ascribed to the increased hydrophobic interactions among various components.

Figure 2. Phase diagram and rheological property. Sol−gel transition phase diagrams of (A) Gel and (B) Gel−MP construct. G′ and G′′ of (C) Gel and (D) Gel−MP construct. SEM was further used for the observation of microstructure of the resulting Gel and Gel−MP construct. As shown in Figure 1C, there was an interconnected pore structure in the polypeptide Gel, which allowed the infiltration of interstitial fluid to accelerate the degradation of polypeptide backbone and also was beneficial to the adhesion of MP. As shown in Figure 1D, MP was observed to be uniformly dispersed on the surface and inside of the Gel after incorporation with Gel (Figure 1D). The size and shape of MP, as well as Gel, did not change


11


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 12 of 27

after the mixing. Stir for three days at 4 °C did not destroy the three-dimensional (3D) structure of MP as benefit of the hydrophobicity and stability of PLGA matrix. All the above results indicated that the Gel−MP construct is suitable as injectable platform for in vivo application.

Figure 3. Degradation, biocompatibility, and drug release. (A) In vitro weight remaining profiles of Gel/CA4−MP/DTX incubated in PBS at pH 7.4 without or with elastase. (B) In vivo biodegradation and biocompatibility of Gel−MP construct. The Gel−MP solution was subcutaneously injected into mice. Photos around the implants were taken at 0 (30 min), 14, 28, and 42 days postinjection. H&E staining images around the implanted Gel after 0, 14, 28, and 42 days of subcutaneous injection of Gel. (C) In vitro CA4 and DTX release from


12

Page 13 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Gel/CA4−MP/DTX incubated in PBS without or with elastase. Statistical data were represented as mean ± standard deviation (SD; n = 3). 3.2. Degradation of Gel−MP Construct and Sequential Drug Delivery. In vitro degradation of Gel−MP construct was performed in different media, that is, PBS and PBS with 2.0 mg mL−1 of elastase (Figure 3A). The degradation rate of Gel−MP construct in the presence of elastase was accelerated and resisted until 50 days compared to 60 days for the PBS group. The in vivo degradation testing was also performed in the rat model. As shown in Figure 3B, the MP-mixed Gel was observed after 30 minutes through subcutaneous injection, and gradually degraded until 42 days. The degradation rate in vivo was faster than that in vitro, which may be caused by the diverse enzymes in subcutaneous layer that accelerated the degradation of Gel−MP construct. Moreover, the slightly local acidic microenvironment caused by the degradation of PLGA was also owed to the speeded up degradation.27-29 At the same time, the biocompatibility of Gel−MP construct was studied by H&E staining. As shown in Figure 3B, after 30 min of the injection, negligible inflammation was detected although the redness of skin was visible in the image. The inflammation turned to be serious after seven days based on the increase of inflammatory cells, and the phenomenon was gradually alleviated through the degradation of the implantation. After 42 days, inflammatory cells were no longer found in the section. The results indicated that there is no safety concern for the using of Gel−MP construct as subcutaneous implantation. In vitro release of CA4 and DTX was conducted in PBS with and without elastase (Figure 3C). Gel/CA4−MP/DTX in PBS with elastase exhibited an accelerated drug release rate, owing to the fast degradation of Gel−MP construct. Around 54% of the loaded DTX was released from DTX Gel/CA4−MP/DTX within 48 days, and no burst release was observed compared to the usage of PLGA MP only as a drug carrier (Supplementary Figure S3).30 The constant release of DTX


13


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 14 of 27

ensured the effective drug concentration in situ and avoided the serious side effects. On the other hand, 90% of CA4 was released from Gel/CA4−MP/DTX in the same period (i.e., 48 days), and a slightly initial burst release was observed in the first eight days resulted from its fast diffusion from Gel surface. CA4 was preferentially released from Gel to disturb tumor vascular and reduce the exchange of nutrients between tumor and surrounding tissues, which also created tissue interstitial space for the penetration of subsequent released DTX to inhibit tumor cell proliferation.

Figure 4. Tumor volume change. Variation of tumor volume in K7 osteosarcoma-grafted mice after peritumoral injection of PBS as control, Gel−MP construct, CA4, DTX, CA4+DTX, Gel/CA4−MP, Gel−MP/DTX, or Gel/CA4−MP/DTX. Data were represented as mean ± SD (n = 10; **P < 0.01, ***P < 0.001). 3.3. Gel/CA4−MP/DTX for Locally Synergistic Chemotherapy of Osteosarcoma. The synergistic effect of the combination of CA4 and DTX in the Gel−MP system was evaluated in the osteosarcoma-xenograft mice model. As shown in Figure 4, the same trend of tumor growth was observed in the control and Gel−MP groups with tumors steadily deteriorating, indicating that the Gel−MP system had no therapeutic effect on osteosarcoma. Compared to the single injection of CA4 or DTX, although the coadministration of CA4 and DTX suppressed tumor


14

Page 15 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


growth efficiently, the safety concern was also detected regarding to the obvious body weight loss. One thing is worth noting: the therapeutic effect of free CA4 was superior to that of free DTX, probably due to the high CA4 concentration in the initial blood of CA4 group which resulted in the shutdown of subcutaneous tumor blood vessels with tumor necrosis. Additionally, the embedding of MP/DTX or CA4 (Gel/CA4−MP or Gel−MP/DTX) in Gel showed enhanced tumor-growth inhibition, owing to the sustained release of the loading drug in a long period. The best tumor-growth suppression was achieved by the treatment of Gel/CA4−MP/DTX, which was attributed to the locally sequential and sustained release of two drugs. The collected tumor was fixed and sectioned for analyzing the antitumor effect of different formulations via the morphology of histopathology by H&E staining. The results were supportive of the highest tumor-suppression efficiency of Gel/CA4−MP/DTX. As shown in Figure 5A, large cell nuclei, and deeply colored and increased split-phase cells were observed in the control and Gel−MP groups, suggesting the rapid proliferation of tumor cells. However, for other groups, nuclear condensation and nuclei dissolution were observed, indicating the progression of tumor cell necrosis. Especially, the fewest tumor cells were found in the group treated with Gel/CA4−MP/DTX, and the necrosis area of tumor tissue was much broader than other groups, both of which supported the best tumor suppression efficiency. Moreover, NISElements imaging software (Nikon Instruments SpA, Florence, Italy) was used to quantify the necrosis area of tumor tissue. Consisting with H&E section results, the largest necrotic area of around 90.5% was achieved in the Gel/CA4−MP/DTX group, which was two times of that of CA4+DTX group as 45.5% (Figure 5B). Some observations are also worth noting. First, the area of necrosis in the control group and Gel−MP group was 2.8% and 3.6%, respectively, which might belong to the spontaneous necrosis changes of tumor cells occurring during the excessive


15


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 16 of 27

development of tumor. Second, in the CA4 and DTX groups, the necrotic areas were only 6.1% and 14.7%, respectively, probably due to the fast diffusion and low concentration of drugs locally. Third, the Gel−MP/DTX and Gel/CA4−MP groups also showed promising tumorgrowth suppression with the necrotic area of 47.9% and 54.1%, respectively. The utilization of injectable Gels as in situ drug carrier could reduce the burst release of drugs and maintain high drug concentration in tumor site to inhibit tumor cell proliferation.

Figure 5. Histopathological analyses and necrotic area statistics. (A) Ex vivo apoptosis analyses of tumor sections in H&E staining and (B) percentage of necrotic area after treatment with PBS


16

Page 17 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


as

control,

Gel−MP,

CA4,

DTX,

CA4+DTX,

Gel/CA4−MP,

Gel−MP/DTX,

or

Gel/CA4−MP/DTX. Statistical data were represented as mean ± SD (n = 3; ***P < 0.001).

Figure 6. Qualitative and semi-quantitative immunofluorescence of CD31. (A) FITC-labeled CD31 staining for evaluation of vascular disrupting efficacy. Green fluorescence indicated the blood vessels stained by FITC-labeled CD31 antibody, and the blue fluorescence represented the nuclei stained by 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI). Statistics of (B) vascular number and (C) area in the CD31-stained sections. Statistical data were represented as mean ± SD (n = 3; **P < 0.01, ***P < 0.001) To further confirm the superior antitumor effect of Gel/CA4−MP/DTX, ex vivo immunohistochemical detections were carried out. Poly (ADP-ribose) polymerase (PARP) and proliferating cell nuclear antigen (PCNA) were applied to analyze the effect of tumor inhibition.


17


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 18 of 27

Platelet endothelial cell adhesion molecule-1 (CD31) was stained for the vascular disrupting efficacy. The tumor vascular structures can be clearly observed through marking the blood vessel epithelial cells by CD31 immunohistochemical staining. As shown in Figure 6A, the groups without CA4 treatment had intensive tumor vascularity, whereas the groups with CA4 treatment showed decreased and irregular blood vessels. The numbers and areas of blood vessels in the control and Gel−MP groups reduced from 16.45 and 15.88 per mm2, to 3.66 per mm2 of the Gel/CA4−MP/DTX group (Figure 6B). Similarly, the vessel area decreased from 8.97 × 103 and 8.31 × 103 μm2 in the control and Gel−MP groups to 2.03 × 103 μm2 in the Gel/CA4−MP/DTX group (Figure 6C), which might be caused by the decrease of capillary blood flow and the blood vessel squeeze by the surrounding tumor cells.

Figure 7. Qualitative and semi-quantitative immunofluorescence of PARP and PCNA. (A) FITC-labeled PARP and PCNA staining of tumor section. Semi-quantitative analyses of immunofluorescence staining: (B) relative fluorescence intensity of PARP and (C) PCNA


18

Page 19 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


analyzed in the PARP- and PCNA-stained sections. Statistical data were represented as mean ± SD (n = 3) Anti-PARP antibody was often used to evaluate the chemotherapeutic drug-induced cell apoptosis, as shown in Figure 7A and 7B. The fluorescence intensity of control and Gel−MP groups was higher than those of all drug-loaded formulations. For example, the fluorescence intensity of the DTX and CA4 groups was 39.7% and 53.6% relative to control group, respectively. The intensifying PARP inhibition signal was observed in the Gel/CA4−MP and Gel−MP/DTX groups, which was consistent with the changes of their tumor volumes. The PARP expression of Gel/CA4−MP/DTX group was reduced to 7.3% compared to that of the control group. Likewise, the PCNA intensity in the groups treated with Gel/CA4−MP/DTX was higher than other group, indicating the effective inhibition of tumor cell proliferation (Figure 7A and 7C).

Figure 8. Variations of body weight and survival rate. (A) Change of body weight and (B) survival rate of K7 osteosarcoma-grafted mice after treatment of PBS as control, Gel−MP, CA4, DTX, CA4+DTX, Gel/CA4−MP, Gel−MP/DTX, or Gel/CA4−MP/DTX. Data were represented as mean ± SD (n = 10; *P < 0.05).


19


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 20 of 27

3.4. Security of Gel/CA4−MP/DTX In Vivo. Safety is one of the most important factors in the potential clinical applications of any advanced chemotherapy drug formulations. In this study, the security of all formulations was established by the changes of body weight, survival rate, and histopathological morphology of visceral organ section.


20

Page 21 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 9. Security in vivo. Ex vivo histological analyses of main organ sections after treatment with PBS as control, Gel−MP construct, CA4, DTX, CA4+DTX, Gel/CA4−MP, Gel−MP/DTX, or Gel/CA4−MP/DTX. Throughout the experiment, the body weights in all groups showed a slight downward trend (Figure 8A). Especially, the mice in the CA4+DTX group had the fastest and most obvious decline. The fastest decline occurred in the first eight days and then gradually slowed down, reflecting toxicity of the large amount injection of the two drugs. Furthermore, the mice of the three Gel−MP groups had no significant decline, indicating Gel−MP had no obvious toxicity to the mice and could decrease the side effects of antitumor drugs. At the same time, the survival rates were monitored during the experiment, as shown in Figure 8B, the results indicated that the survival rates of control and Gel−MP groups were lower than that of all the groups with the application of antitumor drugs. Most fascinatingly, the treatment with Gel/CA4−MP/DTX exhibited the complete survival attributed to the excellent antitumor efficacy and high safety in vivo. To further evaluate the security of all tested formulations, the histopathological analyses of main internal organs (e.g., the heart, liver, spleen, lung, and kidney) were performed through H&E staining after all treatments (Figure 9). The histological morphologies of each organ were observed. The organs of control and Gel−MP groups showed the normal histological morphologies. The results suggested that the Gel−MP construct had no toxicity to body organs. However, all the drug formulation groups exhibited pathological changes in the H&E-stained sections more or less. The organ pathological changes were obviously more serious in the three free drug groups than the three drug-loaded formulation groups. More specifically, direct injection of free CA4 had the most serious damage to liver cells. The hepatocyte turned edema


21


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 22 of 27

and vacuolation. CA4+DTX group had the most severe pulmonary edema and renal capsule cavity shrank, and the most inflammatory cells infiltration in myocardium, hepatocyte, and alveolar walls, because of the combination toxic effects of the two free drugs. This experiment showed that the Gel−MP construct reduced the damage to vital organs, indicating the good prospects for clinical application. 4. CONCLUSIONS Injectable Gel−MP construct with PLAF-b-PEG-b-PLAF and PLGA as the matrices of Gel and MP, respectively, was fabricated for the sequential delivery of CA4 and DTX. After subcutaneous injection, the Gel−MP construct degraded completely in 42 days along with good biocompatibility. For in vivo application, after peritumoral injection, CA4 was first released from Gel/CA4−MP/DTX to destroy the blood vessels in the tumor, and then DTX was sustainably diffused to inhibit cell proliferation, inducing the internal and external apoptosis of osteosarcoma, respectively. The results demonstrated that the construct of Gel−MP construct with sequential degradation exhibited a great potential for stepwise release of double antitumor drugs with different mechanisms for locally synergistic chemotherapy.

ASSOCIATED CONTENT Supporting

Information.

The

following

files

are

available

free

of

charge.

Detailed experimental section; synthetic route and 1H NMR spectrum of PLAF-b-PEG-b-PLAF; rheological analysis of Gel/CA4−MP/DTX; DTX release from MP. AUTHOR INFORMATION Corresponding Authors


22

Page 23 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


*E-mail: [email protected]. *E-mail: [email protected].

Notes The authors declare no competing financial interest.

ACKNOWLEDGMENTS The authors gratefully acknowledged the financial support provided by the National Natural Science Foundation of China (Grant Nos. 51673190, 51303174, 51673187, 51473165, and 51390484). REFERENCES 1.

Mertens, A. C.; Yong, J.; Dietz, A. C.; Kreiter, E.; Yasui, Y.; Bleyer, A.; Armstrong, G. T.;

Robison, L. L.; Wasilewski‐Masker, K., Conditional Survival in Pediatric Malignancies: Analysis of Data from the Childhood Cancer Survivor Study and the Surveillance, Epidemiology, and End Results Program. Cancer 2015, 121 (7), 1108−1117. 2.

Gu, X.; Ding, J.; Zhang, Z.; Li, Q.; Zhuang, X.; Chen, X., Polymeric Nanocarriers for

Drug Delivery in Osteosarcoma Treatment. Curr. Pharm. Design 2015, 21 (36), 5187−5197. 3.

Ottaviani, G.; Jaffe, N., The Epidemiology of Osteosarcoma. In Pediatric and Adolescent

Osteosarcoma, Jaffe, N.; Bruland, O. S.; Bielack, S., Eds. Springer US: Boston, MA, 2010, pp 3−13. 4.

Valery, P. C.; Moore, S. P.; Meiklejohn, J.; Bray, F., International Variations in Childhood

Cancer in Indigenous Populations: A Systematic Review. Lancet Oncol. 2014, 15 (2), e90−e103. 5.

Fan, X. L.; Cai, G. P.; Zhu, L. L.; Ding, G. M., Efficacy and Safety of Ifosfamide-Based


23


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 24 of 27

Chemotherapy for Osteosarcoma: A Meta-Analysis. Drug Des. Dev. Ther. 2015, 9, 5925−5932. 6.

Hattinger, C. M.; Pasello, M.; Ferrari, S.; Picci, P.; Serra, M., Emerging Drugs for High-

Grade Osteosarcoma. Expert Opin. Emerg. Dr. 2010, 15 (4), 615−634. 7.

Ding, J.; Li, C.; Zhang, Y.; Xu, W.; Wang, J.; Chen, X., Chirality-Mediated Polypeptide

Micelles for Regulated Drug Delivery. Acta Biomater. 2015, 11 (0), 346−355. 8.

Chen, J.; Ding, J.; Xiao, C.; Zhuang, X.; Chen, X., Emerging Antitumor Applications of

Extracellularly Reengineered Polymeric Nanocarriers. Biomater. Sci. 2015, 3 (7), 988−1001. 9.

Li, C.; Xu, W.; Ding, J.; Zhang, Y.; Wang, J.; Zhuang, X.; Chen, X., Micellization of

Antineoplastic Agent to Significantly Upregulate Efficacy and Security. Macromol. Biosci. 2015, 15 (3), 328−341. 10.

Yu, L.; Ding, J., Injectable Hydrogels as Unique Biomedical Materials. Chem. Soc. Rev.

2008, 37 (8), 1473−1481. 11.

Cheng, Y.; He, C.; Ding, J.; Xiao, C.; Zhuang, X.; Chen, X., Thermosensitive Hydrogels

Based on Polypeptides for Localized and Sustained Delivery of Anticancer Drugs. Biomaterials 2013, 34 (38), 10338−10347. 12.

Ci, T.; Chen, L.; Yu, L.; Ding, J., Tumor Regression Achieved by Encapsulating a

Moderately Soluble Drug into a Polymeric Thermogel. Sci. Rep. 2014, 4, 5473. 13.

Zhang, Y.; Ding, J.; Sun, D.; Sun, H.; Zhuang, X.; Chang, F.; Wang, J.; Chen, X.,

Thermogel-Mediated Sustained Drug Delivery for in situ Malignancy Chemotherapy. Mater. Sci. Eng. C 2015, 49, 262−268. 14.

Bastiancich, C.; Danhier, P.; Préat, V.; Danhier, F., Anticancer Drug-Loaded Hydrogels as

Drug Delivery Systems for the Local Treatment of Glioblastoma. J. Control. Release 2016, 243, 29−42.


24

Page 25 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


15.

García-González, C. A.; Jin, M.; Gerth, J.; Alvarez-Lorenzo, C.; Smirnova, I.,

Polysaccharide-Based Aerogel Microspheres for Oral Drug Delivery. Carbohyd. Polym. 2015, 117, 797−806. 16.

Floyd, J. A.; Galperin, A.; Ratner, B. D., Drug Encapsulated Polymeric Microspheres for

Intracranial Tumor Therapy: A Review of the Literature. Adv. Drug Deliv. Rev. 2015, 91, 23−37. 17.

Zhao Li, D. J., Xiao Chunsheng, Chen Xuesi, Gai Guangqing, Wang Liyan, Poly(L-

glutamic acid) Microsphere: Preparation and Application in Oral Drug Controlled Release. Acta Chim. Sin. 2015, 73 (1), 60−65. 18.

Kapoor, D. N.; Bhatia, A.; Kaur, R.; Sharma, R.; Kaur, G.; Dhawan, S., PLGA: A Unique

Polymer for Drug Delivery. Ther. Deliv. 2015, 6 (1), 41−58. 19.

Song, W.; Tang, Z.; Zhang, D.; Yu, H.; Chen, X., Coadministration of Vascular Disrupting

Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions. Small 2015, 11 (31), 3755−3761. 20.

Pérez-Pérez, M.-J.; Priego, E.-M.; Bueno, O.; Martins, M. S.; Canela, M.-D.; Liekens, S.,

Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth. J. Med. Chem. 2016, 59 (19), 8685−8711. 21.

Dark, G. G.; Hill, S. A.; Prise, V. E.; Tozer, G. M.; Pettit, G. R.; Chaplin, D. J.,

Combretastatin A-4, An Agent that Displays Potent and Selective Toxicity toward Tumor Vasculature. Cancer Res. 1997, 57 (10), 1829−1834. 22.

Nagaiah, G.; Remick, S. C., Combretastatin A4 Phosphate: A Novel Vascular Disrupting

Agent. Future Oncol. 2010, 6 (8), 1219−1228. 23.

Jain, R. A., The Manufacturing Techniques of Various Drug Loaded Biodegradable

Poly(lactide-co-glycolide) (PLGA) Devices. Biomaterials 2000, 21 (23), 2475−2490.


25


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

24.

Page 26 of 27

He, T.; Li, D.; Yang, Y.; Ding, J.; Jin, F.; Zhuang, X.; Chen, X., Mesomeric Configuration

Makes Polyleucine Micelle an OptimalNanocarrier. Biomater. Sci. 2016, 4 (5), 814−818. 25.

Xu, W.; Ding, J.; Li, L.; Xiao, C.; Zhuang, X.; Chen, X., Acid-Labile Boronate-Bridged

Dextran–Bortezomib Conjugate with Up-Regulated Hypoxic Tumor Suppression. Chem. Commun. 2015, 51 (31), 6812−6815. 26.

Xu, W.; Ding, J.; Xiao, C.; Li, L.; Zhuang, X.; Chen, X., Versatile Preparation of

Intracellular-Acidity-Sensitive

Oxime-Linked

Polysaccharide-Doxorubicin

Conjugate

for

Malignancy Therapeutic. Biomaterials 2015, 54, 72−86. 27.

Vert, M.; Li, S.; Garreau, H., More about the Degradation of LA/GA-Derived Matrices in

Aqueous Media. J. Control. Release 1991, 16 (1-2), 15−26. 28.

Therin, M.; Christel, P.; Li, S.; Garreau, H.; Vert, M., In vivo Degradation of Massive

Poly(α-hydroxy acids): Validation of in vitro Findings. Biomaterials 1992, 13 (9), 594−600. 29.

Grizzi, I.; Garreau, H.; Li, S.; Vert, M., Hydrolytic Degradation of Devices based on

Poly(DL-lactic acid) Size-Dependence. Biomaterials 1995, 16 (4), 305−311. 30.

Gu, B.; Sun, X.; Papadimitrakopoulos, F.; Burgess, D. J., Seeing is Believing, PLGA

Microsphere Degradation Revealed in PLGA Microsphere/PVA Hydrogel Composites. J. Control. Release 2016, 228, 170−178.


26

Page 27 of 27

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


TOC Graphic


27

Injectable HydrogelâMicrosphere Construct with Sequential

Recommend Documents

Injectable HydrogelâMicrosphere Construct with Sequential